J Exp Clin Cancer Res. Targeting targeted agents: open issues for clinical trial design. J Exp ClinCancer Res. Preparing for precision medicine. N Engl J Med. Clinical development success rates for investigational drugs. Nat Biotechnol. Factors associated with failure of oncology drugs in late-stage clinical development: a systematic review. Cancer Treat Rev. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol. Expansion cohorts in first-in-human solid tumor oncology trials. Clin Cancer Res. Acute lymphoblastic leukemia in children.
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute Promyelocytic leukemia: final results of the randomized Italian-German APL trial. J Clin Oncol. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders. New Biotechnol. The evolution of oncology companion diagnostics from signal transduction to Immuno-oncology. Trends Pharmacol Sci. Market watch: where is personalized medicine in industry heading?
Nat Rev Drug Discov. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol. Reports from the clinical and translational cancer research think tank meeting: design strategies for personalized therapy trials. Differential activity of Nivolumab, Pembrolizumab and MPDLA according to the tumor expression of programmed death-Ligand-1 PD-L1 : sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.
Expert Rev Mol Diagn. Understanding pancreatic cancer genomes. J Hepatobiliary Pancreat Sci. Clinical cancer genomics: how soon is now?
- Modern Clinical Trial Analysis.
- English Made Easy Volume Two: Learning English through Pictures: 2;
- Designs for Clinical Trials : David Harrington : ;
- Bal à Korsör (Littérature) (French Edition).
- Modern Clinical Trial Analysis: 0 (Applied Bioinformatics and Biostatistics in Cancer Research)?
J Pathol. Rebooting cancer tissue handling in the sequencing era: toward routine use of frozen tumor tissue. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Whole genomes redefine the mutational landscape of pancreatic cancer. Genomic analyses identify molecular subtypes of pancreatic cancer.
Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Interventions to improve patient understanding of cancer clinical trial participation: a systematic review. Eur J Cancer Care Engl.
Testing violations of the exponential assumption in cancer clinical trials with survival endpoints. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer. Outcomes and endpoints in cancer trials: bridging the divide.
Cancer Immunol Res. Google Scholar Stone A. The shape of curves matters.
Modern Molecular Biology:
When is a seamless study desirable? Case studies from different pharmaceutical sponsors. Pharm Stat. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials. J Biopharm Stat. Integrative clinical genomics of metastatic cancer. Integrative clinical sequencing in the Management of Refractory or relapsed cancer in youth.
Cancer Discov. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting GFPC study Implementing personalized cancer genomics in clinical trials.
Sin-Ho Jung | S[email protected]
Analysis of impact of post-treatment biopsies in phase I clinical trials. Nat Rev Cancer. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. Liquid biopsies: genotyping circulating tumor DNA. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. Mol Oncol. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
Nat Med. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Integrating liquid biopsies into the management of cancer. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. Eur J Cancer. A systematic review of on-site monitoring methods for health-care randomised controlled trials.
Clin Trials. Statistical challenges for central monitoring in clinical trials: a review. Int J Clin Oncol. The impact of clinical trial monitoring approaches on data integrity and cost--a review of current literature. Eur J Clin Pharmacol. Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, lima, ESMO Open. Guidance for industry. Full Text PubMed. Full Text. Research Research Overview. Research Statement. Funded Research. Work with TMIST investigators in the design, development and implementation of data collection forms and procedures, utilizing standard informatics tools and processes.
Collaborate on pilot testing of protocol implementation procedures and data collection. Develop tools for data monitoring and collaborate in the development of data collection tools and database integrations. Monitor and verify the quality of the data, including checks of accuracy, completeness, and timeliness. Provide effective review and quality control of data flowing from data collection systems and monitor protocol compliance. Perform interim and final analyses, as specified in the protocol, and generate relevant reports.
Provide methodologic leadership and support in summarizing and interpreting study findings, and in preparing abstracts, manuscripts, and reports to monitoring bodies, including the DSMC. Address methodologic issues arising in the design and analysis of the study. Role: Faculty Statistician. Scholarly Work. Please see list of publications above. Background Education and Training.
- Designs for Clinical Trials : Perspectives on Current Issues?
- Land Fall.
- Modern Clinical Trial Analysis : Kathleen Branley : .
- Reluctant Medium (Rachel Blackstone Paranormal Mysteries Book 1).
- Slovak-English, English-Slovak Dictionary & Phrasebook.
- Bioinformatics - Wikipedia;
The Journal of Urology. Journal of Nuclear Medicine. Bazan, Jose G. Clinical Statistics This research area deals with innovative methods for clinical trial designs and evaluation strategies for clinical data. Among other topics, we focus on biomarker-driven trials, statistics for personalized medicine, flexible trial designs and analyses of retrospective data collections.
Exploring Characteristics of Omics Data Our main goal is to investigate the defining features for different types of omics data and develop appropriate statistical methods for analysis. This includes high-dimensional genomic data where the implementation of efficient algorithms for model inference is of importance.